Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01042119|
Recruitment Status : Completed
First Posted : January 5, 2010
Last Update Posted : June 24, 2010
The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.
The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.
|Condition or disease|
|Overactive Bladder Syndrome|
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study|
|Study Start Date :||January 2010|
|Actual Primary Completion Date :||June 2010|
|Actual Study Completion Date :||June 2010|
patients who received intravesical injections of botulinum neurotoxin type A
- duration of effect of Botox [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01042119
|University Hospital of Zurich, Clinic for Gynaecology|
|Zurich, Switzerland, 8091|
|Principal Investigator:||David A Scheiner, MD||University Hospital of Zurich, Clinic for Gynaecology|